The role of reduced intensity preparative regimens in patients with thalassemia given hematopoietic transplantation

Annals of the New York Academy of Sciences

Volumn 1202, Issue , 2010, Pages 141-148

  Bertaina, Alice ^a   Bernardo, Maria Ester ^a   Mastronuzzi, Angela ^a   Nasa, Giorgio La ^b   Locatelli, Franco ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b Binaghi Hospital   (Italy)

Author keywords

allogeneic hematopoietic stem cell transplantation; cord blood; reduced intensity preparative regimens; thalassemia; unrelated donors

Indexed keywords

AZATHIOPRINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ERYTHRONOLIDE A; FLUDARABINE; HYDROXYUREA; METHOTREXATE; THIOTEPA; THYMOCYTE ANTIBODY; TREOSULFAN;

ALKYLATION; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGRAFT; ALLOIMMUNIZATION; BONE MARROW TRANSPLANTATION; CHIMERA; CHRONIC HEPATITIS; CONFERENCE PAPER; DISEASE FREE SURVIVAL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROCYTE; ERYTHROID CELL; GRAFT FAILURE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HEMOGLOBINOPATHY; HEPATITIS; HEPATOMEGALY; HUMAN; IMMUNE DEFICIENCY; IRON CHELATION; IRON OVERLOAD; LEUKEMIA; LEUKOCYTE; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; NONMYELOABLATIVE CONDITIONING; REDUCED INTENSITY CONDITIONING; RISK ASSESSMENT; RISK REDUCTION; SICKLE CELL ANEMIA; SPLENOMEGALY; THALASSEMIA; THALASSEMIA MAJOR; TREATMENT OUTCOME; TUMOR ABLATION;

EID: 77955859649     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05590.x     Document Type: Conference Paper

References (40)

1. Olivieri, N.F. 1999. The-thalassemia. N. Engl. J. Med. 34: 99-109.
2. Borgna-Pignatti, C., S. Rugolotto, P. De Stefano, et al. 1998. Survival and disease complications in thalassemia major. Ann. N.Y. Acad. Sci. 850: 227-231.
3. Modell, B., M. Khan & M. Darlison. 2000. Survival in betathalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 355: 2051-2052.
4. Cappellini, M.D., A. Cohen, A. Piga, et al. 2006. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 107: 3455-3462.
5. Borgna-Pignatti, C., M.D. Cappellini, P. De Stefano, et al. 2006. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 107: 3733-3737.
6. Borgna-Pignatti, C., S. Rugolotto, P. De Stefano, et al. 2004. Survival and complications in patients with thalassemiamajor treated with transfusion and deferoxamine. Haematologica 89: 1187-1193.
7. Locatelli, F. & P. De Stefano. 2004. New insights into haematopoietic stem cell transplantation for patients with haemoglobinopathies. Br. J. Haematol. 125: 3-11. (Pubitemid 38453271)
8. Lucarelli, G., R.A. Clift, M. Galimberti, et al. 1999. Bone marrow transplantation in adult thalassemic patients. Blood 93: 1164-1167. (Pubitemid 29076130)
9. Storb, R.F., G. Lucarelli & P.A. McSweeney. 2003. Hematopoietic cell transplantation for benign hematological disorders and solid tumors. Hematol. (Am. Soc. Hematol. Educ. Program) 372-397.
10. Giardini, C. & G. Lucarelli. 1999. Bone marrow transplantation for beta-thalassemia. Hematol. Oncol. Clin. North Am. 13: 1059-1064.
11. Thomas, E.D., C.D. Buckner, J.E. Sanders, et al. 1982. Marrow transplantation for thalassemia. Lancet 2: 227-229.
12. La Nasa, G., C. Giardini, F. Argiolu, et al. 2002. Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes. Blood 99: 4350-4356.
13. La Nasa, G., F. Argiolu, C. Giardini, et al. 2005. Unrelated bone marrow transplantation for beta-thalassemia patients: the experience of the italian bonemarrow transplant group. Ann. N.Y. Acad. Sci. 1054: 186-195.
14. Fleischauer, K., F. Locatelli, M. Zecca, et al. 2006. Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with non-permissive HLA-DPB1 disparity in host-versus-graft direction. Blood 107: 2984-2992.
15. Hongeng, S., S. Pakakasama, A. Chuansumrit, et al. 2006. Outcomes of transplantation with related- and unrelateddonor stem cells in children with severe thalassemia. Biol. Blood Marrow Transplant. 12: 683-687.
16. Locatelli, F., V. Rocha, W. Reed, et al. on behalf of the Eurocord Transplant Group. 2003. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood 101: 2137-2143.
17. Lucarelli, G.,M.Galimberti, P. Polchi, et al. 1990. Bone marrow transplantation in patients with thalassemia. N. Engl. J. Med. 322: 417-421.
18. Lucarelli, G., M. Galimberti, P. Polchi, et al. 1993. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy.N. Engl. J. Med. 329: 840-844.
19. Lucarelli, G., R. Clift, M. Galimberti, et al. 1996. Marrow transplantation for patientswith thalassemia: results inClass 3 patients. Blood 87: 2082-2088.
20. Zino, E.,G.Frumento, S.Marktel, et al. 2004.ATcell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematological stem cell transplantation. Blood 103: 1417-1424.
21. Andreani, M., M. Manna, Lucarelli, G., et al. 1996. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. Blood 87: 3494-3499.
22. Li, C.K., K.W. Chik,K.S. Tsang, et al. 2002.Mixed chimerism after bone marrow transplantation for thalassemia major. Haematologica 87: 781-782.
23. Lisini, D., M. Zecca, G. Giorgiani, et al. 2008. Donor/recipient mixed chimerism does not predict graft failure in children with beta-thalassemia given allogeneic cord blood transplantation from an HLA-identical sibling. Haematologica 93: 1859-1867.
24. Wu, C.J., E.P. Hochberg, S.A. Rogers, et al. 2003. Molecular assessment of erythroid lineage chimerism following nonmyeloablative allogeneic stem cell transplantation. Exp. Haematol. 31: 924-933.
25. Sykes, M., A. Eisenthal & D.H. Sachs. 1988. Mechanism of protection from graft-versus-host disease in murine mixed allogeneic chimeras. Development of a null cell population suppressive of cell-mediated lympholysis responses and derived from the syngeneic bone marrow component. J. Immunol. 140: 2903-2911.
26. Wekerle, T. & M. Sykes. 1999. Mixed hematopoietic chimerism as an approach for the induction of transplantation tolerance. Transplantation 68: 459-467.
27. Diaconescu, R., C.R. Flowers, B. Storer, et al. 2004. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 104: 1550-1558. (Pubitemid 39166537)
28. McSweeney, P.A., D. Niederwieser, J.A. Shizuru, et al. 2001. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97: 3390-3400.
29. Slavin, S., A. Nagler, E. Naparstek, et al. 1998. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91: 756-763.
30. Krishnamurti L.,B.Blazar&J.E.Wagner. 2001. Bonemarrow transplantation withoutmyeloablation in sickle cell anemia. N. Engl. J. Med. 344: 68.
31. Horan J.T., J.L. Liesveld, P. Fenton, et al. 2005. Hematopoietic stemcell transplantation formultiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin. Bone Marrow Transplant. 35: 171-177.
32. Hongeng, S., A. Chuansumrit, P. Hathirat, et al. 2002. Full chimerism in nonmyeloablative stem cell transplantation in a beta-thalassemia major patient (class 3 Lucarelli). Bone Marrow Transplant. 30: 409-410.
33. Zhu K.E., J. Gu & T. Zhang. 2006. Allogeneic stem cell transplantation from unrelated donor for class 3-thalassemia major using reduced-intensity conditioning regimen. Bone Marrow Transplant. 37: 111-112.
34. Locatelli F. 2006. Reduced-intensity regimens in allogeneic hematopoietic stem cell transplantation for hemoglobinopathies. Hematol. (Am. Soc. Hematol. Educ. Program) 398-401.
35. Iannone, R., J.F. Casella, E.J. Fuchs, et al. 2003. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and-thalassemia. Biol. Blood Marrow Transplant. 9: 519-528.
36. Sodani, P., D. Gaziev, P. Polchi, et al. 2004. A new approach for bone marrow transplantation in class 3 thalassemic patients aged less than 17 years. Blood 104: 1201-1203.
37. Casper J., W. Knauf, T. Kiefer, et al. 2004. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stemcell transplantation. Blood 103: 725-731.
38. Holowiecki J., S. Giebel, J. Wojnar, et al. 2008. Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronicmyeloid leukaemia. Br. J. Haematol. 142: 284-292.
39. Ploemacher R.E., K.W. Johnson, E.J.C. Rombouts, et al. 2004. Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model. Biol. Blood Marrow Transplant. 10: 236-245.
40. Bernardo M.E., M. Zecca, E. Piras, et al. 2008. Treosulfanbased conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major. Br. J. Haematol. 143: 548-551.